Company: LAZ
Filing Date: 2025-07-29
Form Type: 424B5
Source: 0001311370-25-000033
Chunk: 13

Company: Lazard, Inc.
Filing Date: 2025-07-29
Form: 424B5
Chunk 13
---
 automated quotation system. In addition, market making activity will be subject to the limits imposed by the Exchange Act. See “Underwriting (Conflicts of Interest).”                                                                                                                                                                                                                                                                                                                                                    |
| Use of Proceeds                                     |     | Lazard Group estimates that it will receive net proceeds of approximately $296.5 million from this offering, after deducting underwriting discounts and other expenses. Lazard Group intends to use the net proceeds from this offering (i) to repurchase any and all of its outstanding 2027 Notes that are validly tendered and not validly withdrawn and accepted for purchase pursuant to the Tender Offer, (ii) to repurchase, redeem, repay at maturity, or otherwise retire any 2027 Notes that may remain outstanding following the Tender Offer, and (iii) to pay fees and expenses related to the foregoing. Lazard Group intends to use any remaining amount of the net proceeds for general corporate purposes. See “Summary—Recent Developments.” |
| Further Issuances                                   |     | As described under “Description of Notes—Further Issuances,” under the indenture we can issue additional notes at later dates. In addition, we can issue additional series of debt securities without limitation as to aggregate principal amount under the indenture in the future.                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

<div align='center'>S-12</div>

| Conflicts of Interest |     | We own all the outstanding equity interests of Lazard Frères & Co. LLC, an underwriter in this offering. As a result, this offering is being conducted in accordance with Rule 5121 of the regulations of the Financial Industry Regulatory Authority (“FINRA”). Pursuant to FINRA Rule 5121, Lazard Frères & Co. LLC may not make sales in this offering to any discretionary account without the prior approval of the customer. See “Underwriting (Conflicts of Interest).” |
| Trustee               |     | The Bank of New York Mellon.                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div align='center'>S-13</div>

### RISK FACTORS
You should carefully consider the following risk factors and the risk factors incorporated by reference into this prospectus supplement and the accompanying prospectus and all of the other information set forth in this prospectus supplement and the accompanying prospectus or incorporated by reference herein or therein before deciding to purchase the notes. For a discussion of the risks related to our business, see “Item 1A. Risk Factors” in the 2024 Form 10-K, as updated by annual